10-Q: Quantum Genesis AI Corp. Q3 2026 10-Q Filing

Quantum Genesis AI Corp. reports a net loss of $24,912 for Q3 2026, with significant operating expenses and a substantial accumulated deficit, raising going concern doubts.

Summary

• Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) filed its Form 10-Q for the quarterly period ended April 30, 2026.
• The company reported no revenues for the three and nine months ended April 30, 2026, and 2025.
• Operating expenses for the three months ended April 30, 2026, were $19,083, a decrease from $60,453 in the same period of 2025, attributed to lower professional fees.
• For the nine months ended April 30, 2026, operating expenses were $59,661, down from $145,921 in the prior year, also due to reduced professional fees.
• Net loss for the three months ended April 30, 2026, was $24,912, an improvement from a net loss of $65,763 in the prior year.
• The net loss for the nine months ended April 30, 2026, was $4,404,437, a significant increase from $161,092 in the same period of 2025, largely due to a loss on conversion of debt.
• The company has an accumulated deficit of $10,041,004 as of April 30, 2026.
• Cash used in operating activities for the nine months ended April 30, 2026, was $62,953.
• The company's financial statements are prepared on a going concern basis, but the incurred net losses, accumulated deficits, and cash used in operations raise substantial doubt about its ability to continue as a going concern.
• The company is dependent on securing future funding through the sale of securities or outside sources.
• As of April 30, 2026, the company had total current assets of $59 and total current liabilities of $443,313, resulting in a working capital deficit of $443,254.
• Management concluded that disclosure controls and procedures, and internal control over financial reporting were not effective due to limited internal resources and lack of multiple transaction review levels.
• A material weakness in financial reporting exists due to a lack of segregation of duties, limited resources, and personnel.
• The company's intellectual property includes proprietary enzyme design technologies and computational methodologies, with a patent application filed for modified polypeptides for enzymatic synthesis of Ibuprofen.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant financial distress, lack of revenue, substantial losses, and explicit concerns about the company's ability to continue as a going concern.

Positives

• Decrease in operating expenses for both the three-month and nine-month periods ended April 30, 2026, compared to the prior year, primarily due to reduced professional fees.
• Net loss for the three months ended April 30, 2026, decreased to $24,912 from $65,763 in the prior year.
• The company has secured intellectual property related to enzyme design technologies and computational methodologies, including a patent application for modified polypeptides for enzymatic synthesis of Ibuprofen.
• Financing activities provided $62,428 in cash for the nine months ended April 30, 2026.

Negatives

• No revenues were earned for the three and nine months ended April 30, 2026, or 2025.
• Significant net loss of $4,404,437 for the nine months ended April 30, 2026, compared to $161,092 in the prior year, driven by a substantial loss on conversion of debt ($4,325,872).
• Accumulated deficit of $10,041,004 as of April 30, 2026.
• Working capital deficit of $443,254 as of April 30, 2026.
• Substantial doubt exists about the company's ability to continue as a going concern due to ongoing losses and cash burn.
• The company is entirely dependent on future funding, with no firm agreements in place.
• Disclosure controls and procedures, and internal control over financial reporting are not effective due to limited resources and personnel.
• A material weakness in financial reporting exists due to a lack of segregation of duties.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to recurring net losses, accumulated deficits, and negative operating cash flow.
• The company is entirely dependent on its ability to attract and receive funding from the sale of securities or outside sources, with no assurance that such funds will be available on acceptable terms.
• Failure to obtain sufficient funding will restrict the company's ability to grow and may require suspension of operations.
• Any additional equity financing may involve substantial dilution to existing stockholders.
• The company's intellectual property is based on a patent application, and there is no guarantee that the patent will be granted or that it will be commercially successful.
• The company's financial disclosure controls and procedures, and internal control over financial reporting are not effective, increasing the risk of material misstatements in financial reports.
• A material weakness in financial reporting exists due to a lack of segregation of duties, which could lead to undetected misstatements.
• The company may become involved in various lawsuits and legal proceedings in the ordinary course of business, which could have an adverse effect.

Future Outlook

The company expects its operating expenses to increase in future years due to increased operating activity under its business model. The company's ability to continue operations and grow is entirely dependent on its ability to secure future funding.

Management Comments

• Management believes that, pursuant to the APA, it acquired the underlying intellectual property and associated rights.
• Management concluded that disclosure controls and procedures, and internal control over financial reporting were not effective due to the company's limited internal resources and lack of ability to have multiple levels of transaction review.
• Management believes that the financial statements and other information presented herewith are materially correct.
• Management does not expect that its disclosure controls and procedures, or its internal controls over financial reporting will prevent all error and all fraud, as a control system can only provide reasonable, not absolute, assurance.
• Management has determined that a material weakness exists due to a lack of segregation of duties, resulting from the company's limited resources and personnel.
• Management intends to take practical, cost-effective steps in implementing internal controls, including hiring additional personnel and potentially forming an audit committee, upon obtaining sufficient capital and operations.

Industry Context

StockSavvy.ai notes that Quantum Genesis AI Corp. operates in the AI and biotechnology sectors, focusing on enzyme catalyst biotransformation. The company's reliance on intellectual property, particularly patent applications, is common in these innovation-driven industries. However, the significant operating losses and going concern issues are critical red flags, especially in a capital-intensive field where substantial R&D investment is required.

Comparison to Industry Standards

• Companies in the AI and biotechnology sectors typically require substantial upfront investment and often operate at a loss for extended periods during research and development phases. However, successful companies in these fields usually demonstrate a clear path to revenue generation and profitability, supported by robust funding rounds or strategic partnerships.
• Quantum Genesis AI Corp.'s current financial state, with no revenue and a significant accumulated deficit, is considerably weaker than many early-stage companies in these sectors that have secured venture capital or other forms of substantial funding to support their growth and development.
• The company's reliance on a single patent application for its core intellectual property is a common strategy, but industry leaders often possess a diversified portfolio of patents and proprietary technologies to mitigate risk and ensure a competitive edge.

Corporate Governance

Legal Proceedings

• Management is currently not aware of any legal proceedings or claims that could have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• As of April 30, 2026, the amount due to related parties was $16,602, and as of July 31, 2025, it was $17,002. These amounts are non-interest bearing and due on demand.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financing, and risk of loss if operations are suspended due to lack of funding. Current share value is likely impacted by going concern issues.
• Creditors: The company's ability to meet its obligations is uncertain due to its financial condition and reliance on future funding.
• Employees: Potential risk to employment if operations are curtailed or suspended due to insufficient capital.
• Suppliers: Potential for delayed payments or non-payment if the company faces severe liquidity issues.

Next Steps

• The company intends to take practical, cost-effective steps in implementing internal controls, including assessing personnel duties, potentially hiring additional personnel, and considering the formation of an audit committee, upon obtaining sufficient capital and operations.
• The company must secure future funding to continue operations and development plans.

Key Dates

Recommendation

The company exhibits severe financial distress with no revenue, significant and increasing net losses, a substantial accumulated deficit, and explicit concerns about its ability to continue as a going concern. The lack of effective internal controls and a material weakness in financial reporting further exacerbate the risks. While the company has intellectual property, its current financial state and dependence on future, unsecured funding make it a highly speculative investment with a significant downside risk.

Keywords

Quantum Genesis AI Corp, Quantumzyme Corp, 10-Q Filing, Quarterly Report, Financial Statements, Net Loss, Going Concern, Operating Expenses, Intellectual Property, Patent Application, AI, Enzyme Catalyst, Biotechnology, Nevada